

12 February 2026

**Physiomics plc**  
**("Physiomics" or the "Company")**

**Physiomics Awarded New Contract**

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new biopharmaceutical client headquartered in South Korea.

This new project is with a South Korean clinical stage biopharmaceutical company focused on the development of next-generation antibody drug conjugate (ADC) and Immuno-oncology therapeutic for the treatment of cancer. Under the terms of the contract, Physiomics will use PK/PD modelling and simulation techniques to support dosing decisions for one of the client's clinical stage assets. The project, valued at up to £66,600, will commence immediately with completion anticipated within the next two months.

**Dr Peter Sargent, CEO of Physiomics, commented:**

*"We are thrilled to have been selected to partner with this new South Korean client on their important clinical stage programme. This engagement underscores Physiomics' continued commitment to deliver robust quantitative insights that de-risk development strategies and enhance decision making, whilst reflecting the Company's efforts to reach new clients in markets further afield. We look forward to applying our expertise to support this client in achieving their development goals."*

For more information about Physiomics and its services, please visit [www.physiomics.co.uk](http://www.physiomics.co.uk).

**Enquiries:**

**Physiomics plc**

Dr Peter Sargent, CEO

+44 (0)1235 841575

**Hybridan LLP (Broker)**

Claire Louise Noyce

+44 (0) 203 764 2341

**Strand Hanson Ltd (NOMAD)**

James Dance & James Bellman

+44 (0)20 7409 3494

**Notes to Editor**

**About Physiomics**

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting edge

making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAVFLFFQLLXBBL